Kalvista Pharmaceuticals Inc (KALV)

Dec 20, 2024

KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada

Dec 20, 2024

Dec 18, 2024

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha

Dec 18, 2024

Dec 18, 2024

BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia

Dec 18, 2024

Dec 18, 2024

KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha

Dec 18, 2024

Dec 18, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat

Dec 18, 2024

Dec 18, 2024

Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 18, 2024

Dec 18, 2024

B of A Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN

Dec 18, 2024

Dec 17, 2024

KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada

Dec 17, 2024

Dec 16, 2024

KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com

Dec 16, 2024

Dec 16, 2024

KalVista appoints new COO amid operational growth - Investing.com

Dec 16, 2024

Dec 16, 2024

KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth - TipRanks

Dec 16, 2024

Dec 16, 2024

KalVista Pharmaceuticals appoints Jeb Ledell as COO - Seeking Alpha

Dec 16, 2024

Dec 16, 2024

KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian

Dec 16, 2024

Dec 13, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 10, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Dec 10, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada

Dec 09, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com

Dec 09, 2024

Dec 09, 2024

What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat

Dec 09, 2024

Dec 08, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Dec 08, 2024

Dec 07, 2024

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Dec 07, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook - Investing.com

Dec 06, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria

Dec 06, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks

Dec 05, 2024

Dec 05, 2024

180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat

Dec 05, 2024

Dec 05, 2024

KalVista Pharmaceuticals Inc. (KALV) reports earnings - Quartzy

Dec 05, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - citybiz

Dec 05, 2024

Dec 05, 2024

Citigroup Inc. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 05, 2024

Dec 04, 2024

Trading (KALV) With Integrated Risk Controls - Stock Traders Daily

Dec 04, 2024

Dec 04, 2024

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com

Dec 04, 2024

Dec 04, 2024

KalVista Pharmaceuticals Awards Inducement Stock Options to New Executive Team Members - StockTitan

Dec 04, 2024

Dec 04, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World

Dec 04, 2024

Dec 03, 2024

Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Rises By 7.3% - MarketBeat

Dec 03, 2024

Nov 29, 2024

Vestal Point Capital LP Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Nov 29, 2024

Nov 28, 2024

KalVista Pharmaceuticals' chief medical officer sells $21,586 in stock - Investing.com India

Nov 28, 2024

Nov 27, 2024

KalVista Pharmaceuticals' chief medical officer sells $21,586 in stock By Investing.com - Investing.com Nigeria

Nov 27, 2024

Nov 27, 2024

KalVista Pharmaceuticals' chief development officer sells $19,378 in stock - Investing.com India

Nov 27, 2024

Nov 27, 2024

KalVista Pharmaceuticals' chief development officer sells $19,378 in stock By Investing.com - Investing.com Australia

Nov 27, 2024

Nov 27, 2024

Insiders At KalVista Pharmaceuticals Sold US$2.5m Of Stock Potentially Indicating Weakness - Simply Wall St

Nov 27, 2024

Nov 27, 2024

KalVista appoints biotech veteran to board By Investing.com - Investing.com Canada

Nov 27, 2024

Nov 26, 2024

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors - citybiz

Nov 26, 2024

Nov 26, 2024

KalVista appoints biotech veteran to board - Investing.com

Nov 26, 2024

Nov 26, 2024

KalVista Pharmaceuticals Appoints Laurence Reid to Board - TipRanks

Nov 26, 2024